Type II endometrial cancers: A case series

Flora Lobo, Eliz Thomas

Research output: Contribution to journalArticle

Abstract

Introduction: Endometrial carcinoma ranks 3rd in India among gynecological malignancies. Endometrial cancer (EC) can be classified into two distinct groups - type I and type II, based on histology, which differs in molecular, clinical and histopathological profiles. Type II is nonestrogen dependent, nonendometrioid, more aggressive and carries poor prognosis. Although type II cancers contribute only about 10% of EC incidence, they present at advanced age and cause approximately 50% recurrence and deaths with a low 5-year, overall survival rate. Type II EC are also characterized by genetic alterations in p53, human epidermal growth factor-2/neu, p16 and E-cadherin. Materials and Methods: Endometrial carcinomas diagnosed from endometrial biopsies and hysterectomy specimens received in the Department of Pathology, Kasturba Medical College, Mangalore, from January 2007 to June 2012 were included in the study. Clinicopathological analysis of the 84 cases of EC was done with emphasis on morphology. p53 immunostaining was performed in two cases of serous carcinoma. Results: Out of a total of 84 cases of EC, ten cases were of type II (11.9%). Out of which, eight were serous carcinoma (9.5%) and two clear cell (2.4%). p53 immunostain was strongly positive in the serous papillary carcinomas. The age of the patients ranged from 45 to 75 years. Myometrial invasion was more than half. Treatment was hysterectomy followed by aggressive chemotherapy. Conclusion: Of the type II EC, serous carcinoma is the most common type. Clinical presentation and prognosis differs in comparison to type I EC, thus the recognition of this type of EC is pivotal.

Original languageEnglish
Pages (from-to)69-72
Number of pages4
JournalJournal of Mid-Life Health
Volume7
Issue number2
DOIs
Publication statusPublished - 01-04-2016

Fingerprint

Endometrial Neoplasms
cancer
Carcinoma
Hysterectomy
Papillary Carcinoma
invasion
pathology
Cadherins
Epidermal Growth Factor
incidence
India
Neoplasms
Histology
Survival Rate
death
Pathology
Biopsy
cause
Recurrence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Health(social science)

Cite this

Lobo, Flora ; Thomas, Eliz. / Type II endometrial cancers : A case series. In: Journal of Mid-Life Health. 2016 ; Vol. 7, No. 2. pp. 69-72.
@article{fcd8c7b07c5b40f39f202131e4253302,
title = "Type II endometrial cancers: A case series",
abstract = "Introduction: Endometrial carcinoma ranks 3rd in India among gynecological malignancies. Endometrial cancer (EC) can be classified into two distinct groups - type I and type II, based on histology, which differs in molecular, clinical and histopathological profiles. Type II is nonestrogen dependent, nonendometrioid, more aggressive and carries poor prognosis. Although type II cancers contribute only about 10{\%} of EC incidence, they present at advanced age and cause approximately 50{\%} recurrence and deaths with a low 5-year, overall survival rate. Type II EC are also characterized by genetic alterations in p53, human epidermal growth factor-2/neu, p16 and E-cadherin. Materials and Methods: Endometrial carcinomas diagnosed from endometrial biopsies and hysterectomy specimens received in the Department of Pathology, Kasturba Medical College, Mangalore, from January 2007 to June 2012 were included in the study. Clinicopathological analysis of the 84 cases of EC was done with emphasis on morphology. p53 immunostaining was performed in two cases of serous carcinoma. Results: Out of a total of 84 cases of EC, ten cases were of type II (11.9{\%}). Out of which, eight were serous carcinoma (9.5{\%}) and two clear cell (2.4{\%}). p53 immunostain was strongly positive in the serous papillary carcinomas. The age of the patients ranged from 45 to 75 years. Myometrial invasion was more than half. Treatment was hysterectomy followed by aggressive chemotherapy. Conclusion: Of the type II EC, serous carcinoma is the most common type. Clinical presentation and prognosis differs in comparison to type I EC, thus the recognition of this type of EC is pivotal.",
author = "Flora Lobo and Eliz Thomas",
year = "2016",
month = "4",
day = "1",
doi = "10.4103/0976-7800.185335",
language = "English",
volume = "7",
pages = "69--72",
journal = "Journal of Mid-Life Health",
issn = "0976-7800",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

Type II endometrial cancers : A case series. / Lobo, Flora; Thomas, Eliz.

In: Journal of Mid-Life Health, Vol. 7, No. 2, 01.04.2016, p. 69-72.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Type II endometrial cancers

T2 - A case series

AU - Lobo, Flora

AU - Thomas, Eliz

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Introduction: Endometrial carcinoma ranks 3rd in India among gynecological malignancies. Endometrial cancer (EC) can be classified into two distinct groups - type I and type II, based on histology, which differs in molecular, clinical and histopathological profiles. Type II is nonestrogen dependent, nonendometrioid, more aggressive and carries poor prognosis. Although type II cancers contribute only about 10% of EC incidence, they present at advanced age and cause approximately 50% recurrence and deaths with a low 5-year, overall survival rate. Type II EC are also characterized by genetic alterations in p53, human epidermal growth factor-2/neu, p16 and E-cadherin. Materials and Methods: Endometrial carcinomas diagnosed from endometrial biopsies and hysterectomy specimens received in the Department of Pathology, Kasturba Medical College, Mangalore, from January 2007 to June 2012 were included in the study. Clinicopathological analysis of the 84 cases of EC was done with emphasis on morphology. p53 immunostaining was performed in two cases of serous carcinoma. Results: Out of a total of 84 cases of EC, ten cases were of type II (11.9%). Out of which, eight were serous carcinoma (9.5%) and two clear cell (2.4%). p53 immunostain was strongly positive in the serous papillary carcinomas. The age of the patients ranged from 45 to 75 years. Myometrial invasion was more than half. Treatment was hysterectomy followed by aggressive chemotherapy. Conclusion: Of the type II EC, serous carcinoma is the most common type. Clinical presentation and prognosis differs in comparison to type I EC, thus the recognition of this type of EC is pivotal.

AB - Introduction: Endometrial carcinoma ranks 3rd in India among gynecological malignancies. Endometrial cancer (EC) can be classified into two distinct groups - type I and type II, based on histology, which differs in molecular, clinical and histopathological profiles. Type II is nonestrogen dependent, nonendometrioid, more aggressive and carries poor prognosis. Although type II cancers contribute only about 10% of EC incidence, they present at advanced age and cause approximately 50% recurrence and deaths with a low 5-year, overall survival rate. Type II EC are also characterized by genetic alterations in p53, human epidermal growth factor-2/neu, p16 and E-cadherin. Materials and Methods: Endometrial carcinomas diagnosed from endometrial biopsies and hysterectomy specimens received in the Department of Pathology, Kasturba Medical College, Mangalore, from January 2007 to June 2012 were included in the study. Clinicopathological analysis of the 84 cases of EC was done with emphasis on morphology. p53 immunostaining was performed in two cases of serous carcinoma. Results: Out of a total of 84 cases of EC, ten cases were of type II (11.9%). Out of which, eight were serous carcinoma (9.5%) and two clear cell (2.4%). p53 immunostain was strongly positive in the serous papillary carcinomas. The age of the patients ranged from 45 to 75 years. Myometrial invasion was more than half. Treatment was hysterectomy followed by aggressive chemotherapy. Conclusion: Of the type II EC, serous carcinoma is the most common type. Clinical presentation and prognosis differs in comparison to type I EC, thus the recognition of this type of EC is pivotal.

UR - http://www.scopus.com/inward/record.url?scp=85018691878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018691878&partnerID=8YFLogxK

U2 - 10.4103/0976-7800.185335

DO - 10.4103/0976-7800.185335

M3 - Article

AN - SCOPUS:85018691878

VL - 7

SP - 69

EP - 72

JO - Journal of Mid-Life Health

JF - Journal of Mid-Life Health

SN - 0976-7800

IS - 2

ER -